Ecthyma gangrenosum (EG) is a rare, infective skin disease, predominantly but not exclusively caused by *Pseudomonas aeruginosa*. It is often seen in individuals with immunosuppression, although it has also been reported among previously healthy individuals. It was initially thought to be pathognomonic of *P. aeruginosa* septicaemia, but this assertion was discarded following several reports on EG without bacteremia and EG with varied bacterial and fungal etiologies. There are scant reports of its association with human immunodeficiency virus (HIV) infection, while ocular involvement is extremely rare. An extensive search of the literature also found no report on EG, nor its relationship with HIV/acquired immunodeficiency syndrome (AIDS) from Sub-Saharan Africa. We hereby present a fatal case of multiple EG lesions in a 44-year-old Nigerian female with AIDS in the absence of bacteremia and review the literature of its association with HIV/AIDS and its concurrent orbital involvement.

**Keywords:** Acquired immunodeficiency syndrome, ecthyma gangrenosum, human immunodeficiency virus, panophthalmitis, *Pseudomonas aeruginosa*

**INTRODUCTION**

Ecthyma gangrenosum is a rare ulcerocutaneous infection previously thought to be solely caused by pseudomonas aeruginosa septicaemia, often with associated neutropenia.(1) It is common in individuals with suppressed immunity of varied aetiologies, including but not limited to haematologic disorders (malignancies and bone marrow suppression); lymphoproliferative disorders; and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.(2–5) *Pseudomonas aeruginosa* remains the commonest cause of EG, but it is also known to be caused by a variety of pathogens, can occur with normal neutrophil counts, and affects both immunocompetent adults and children. (5)Although HIV/AIDS can cause profound immunosuppression, only a handful of articles report on EG in association with HIV/AIDS, and none with concomitant panophthalmitis. This article reports on a case of a woman with AIDS who developed oculocutaneous ecthyma gangrenosum with a fatal outcome.

**Case Report**

A 44-year-old woman admitted via the emergency department with a 3-month history of multiple ulcers and a 3-day history of rapidly progressive swelling and loss of vision in the right eye with associated fever. She had been diagnosed with human immunodeficiency virus (HIV)-infection 5 years previously, was placed on antiretroviral medications, but defaulted 3 months before presentation.

Before her contact with our team, she had been admitted on account of multiple expanding ulcers with purulent discharge and managed as a case of pyomyositis. After a 3-week stay in the hospital, she requested discharge as some ulcers had healed, while others were improving. Her CD4+ count was 67 cells/mm³.

She returned after 2 weeks on noticing the expansion of previously healing ulcers and the development of rapidly evolving new lesions. Concurrently, there was right ocular involvement.

**Address for correspondence:** Dr. Eshan B. Henshaw, Department of Internal Medicine, University of Calabar, Calabar, Cross River State, Nigeria. E-mail: eshenshaw@unical.edu.ng
pain, swelling, and discharge, with progressively worsening visual loss.

Skin lesions were located on thighs, upper limbs, buttocks, perineum, and right eyelid, often beginning as discrete painful papules or pustules, with rapid progression (within 5–7 days) to pus formation, discharge, and eventual ulceration [Figures 1 and 2]. Examination revealed multiple ulcers on the aforementioned locations in various stages of evolution. The largest on the left thigh measured 6 cm × 10 cm, had an irregular undermined edge, with slough and islands of necrotic eschar on the ulcer floor. Ophthalmologic assessment of the right eye revealed upper lid edema with mild erythema and an overlying crusted and necrotic lesion on the nasal aspect. The conjunctiva, cornea, and sclera were all necrotic. A clinical diagnosis of ecthyma gangrenosum (EG) was entertained by the dermatologists, while panophthalmitis of the right eye was the presumptive diagnosis made by the ophthalmologists. She was commenced on intravenous levofloxacin, and her right eye was eviscerated and sent for histology. Intraoperative findings were extensive scleral necrosis, melted cornea, but relatively clear vitreous.

The white cell count was $4.5 \times 10^9/L$ with 46% neutrophils (normal 4–11 \times 10^9/L), while hematocrit was 20% (normal 36%–45%). Blood culture was negative; wound biopsy revealed an ulcerated epithelium with vascular congestion and areas of dermal hemorrhage and necrosis. There were also chronic inflammatory cells with features of hemorrhagic vasculitis. Culture of the specimen yielded growth of Pseudomonas aeruginosa sensitive only to ceftazidime, with intermediate sensitivity to ceftazidime, but resistant to levofloxacin, ciprofloxacin, and gentamicin. A concurrent definitive diagnosis of EG was eventually entertained by both dermatologists and ophthalmologists. Levofloxacin was discontinued and cefepime prescribed. The patient was, however, unable to procure the requisite medications, with a progressive deterioration in her clinical status, and eventual demise after 71 days of admission.

**Discussion**

The pathogenic effect of Bacillus pyocyaneus (now known as P. aeruginosa) in humans was fully elucidated in 1897 by Barker. He mentioned its myriad organ system affection, and described the varied forms of cutaneous and subcutaneous manifestations, one of which himself and colleague (Fowler) referred to as “gangrenous processes”. This is suggestive of the morphologic characteristic of EG. This and subsequent reports set the stage for EG to be considered a pathognomonic cutaneous sign of P. aeruginosa septicemia, mostly occurring in immunocompromised patients who were also neutropenic.

Following these initial findings, several authors have documented the presence of EG without bacteremia, EG without neutropenia, and EG in immunocompetent individuals. Like in our index patient, P. aeruginosa is often the causative agent of most cases of EG; however, many other infective agents have been implicated, including other Gram-negative/gram-positive bacterial and fungal organisms in some rare cases, more than one organism have been detected.

Immunosuppressive states remain the most common risk factor for the development of EG, among which malignancies, particularly hematological malignancies, and lymphoproliferative disorders preponderate. This is clearly evident in a number of case series reported. However, reports of EG in HIV/acquired immunodeficiency syndrome (AIDS) have been relatively few. The first of such was by Sangeorzan et al. who reported two patients with skin lesions caused by P. aeruginosa, one of which was EG. The following year, el Baze published a case series of 19 immunosuppressed patients with P. aeruginosa-induced dermatoses, ten of which were EG and only one was associated with HIV/AIDS. Inclusive of our index patient, there are a total of 16 reports of EG in association with HIV/AIDS to date [Table 1]. In all but three cases, the causative agent was P. aeruginosa, and only a quarter of those with P. aeruginosa-related EG had bacteremia at time of presentation. Ninety percent of the stated CD4+ counts were ≤100 cells/ml, indicating that EG is indeed a disease of advanced HIV/AIDS. The mortality rate in this series of
patients was 12.5% (inclusive of our index case) and both had widespread lesions in multiple sites in the absence of bacteremia. This is significantly lower than the mortality rate of 80% quoted by Kim et al.\(^7\)

A much rare finding in our patient was the orbital involvement – panophthalmitis, which coexisted with the skin manifestation. To the best of our knowledge, only once, such an association has been reported.\(^34\) A similar report involved the concurrent presentation of EG with orbital cellulitis and endophthalmitis – a less extensive involvement of the orbital tissues than panophthalmitis.\(^35\) More commonly observed are reports of periorbital EG, which was also present on the right eyelid of our patient.\(^36-38\)

The fatal outcome in our patient was subsequent to the observed drug resistance to the commonly used, available, and affordable antibiotics, with eventual progression of the infection occasioned by her inability to procure the requisite, but expensive antibiotics to which the infection showed sensitivity. A high prevalence of antibiotic resistance exists in Nigeria and is responsible for the increased mortality observed in the management of communicable diseases.\(^39\) As stated by Greene et al.,\(^3\) multiple EG lesions and delay in initiating the appropriate therapy are some of the factors that correlate with poorer outcome, which were present in our patient.

### Conclusion

EG remains a potentially fatal communicable disease, especially in developing countries where the dearth of reports results in a low level of awareness, a low index of suspicion, and delay in instituting the requisite therapy. Although EG may be an uncommon cutaneous manifestation of HIV/AIDS, it should be included in the differential diagnosis of ulcerative communicable disorders in advanced HIV/AIDS. Multiple lesions of EG, even without bacteremia, may be associated with increased mortality.

### Table 1: Demographic, clinical, and laboratory data of patients with human immunodeficiency virus/acquired immunodeficiency syndrome and ecthyma gangrenosum

| Age (years) | Sex | Body location | Duration of HIV diagnosis | CD4 count (cells/mm\(^3\)) | Neutropenia | Wound culture done | Presence of bacteremia | Organism cultured | Outcome | Author(s)       |
|------------|-----|---------------|---------------------------|-----------------------------|-------------|--------------------|------------------------|-------------------|---------|-----------------|
| 35         | Male | Face          | NS                        | 17                          | No          | Yes                | Yes                    | Yes               | Survived | Kim et al., 1999\(^7\) |
| 19         | Female | NS            | NS                        | 15 years                    | 4           | Yes                | No                                   | No               | MRSA     | Cao et al., 2011\(^25\) |
| 40         | Male | Trunk, LL     | NS                        | 15 years                    | 5 years     | Yes                | No                                   | No               | P. aeruginosa | Ungprasert et al., 2013\(^39\) |
| 33         | Male | Trunk, buttocks | NS                       | 5 days                      | 11          | Yes                | No                                   | No               | P. aeruginosa | Ferguson et al., 2017\(^33\) |
| 31         | Male | Face          | NS                        | 11                          | No          | Yes                | Yes                                  | No               | P. aeruginosa | Khan et al., 2000\(^27\) |
| 45         | Female | LL            | NS                        | 70                          | No          | Yes                | Yes                                  | No               | P. aeruginosa | Khan et al., 2000\(^27\) |
| 45         | Male | Buttocks      | NS                        | 70                          | No          | Yes                | Yes                                  | No               | P. aeruginosa | Berger et al., 1995\(^25\) |
| 36         | Male | Genitalia     | NS                        | 70                          | No          | Yes                | Yes                                  | No               | P. aeruginosa | Berger et al., 1995\(^25\) |
| 62         | Female | Neck, perineum, LL | 12 years            | 17                          | No          | Yes                | Yes                                  | No               | MSSA     | Buffière-Morgado et al., 2015\(^52\) |
| 22         | Male | LL, genitalia | NS                        | 4 years                     | Yes         | Yes                | No                                   | No               | P. aeruginosa | Nelson et al., 1991\(^24\) |
| 61         | Male | LL            | NS                        | 5 months                    | 8           | No                 | No                                   | No               | NTM      | Techatawepisarn et al., 2013\(^30\) |
| 35         | Male | LL            | NS                        | 50                          | 8           | No                 | No                                   | No               | P. aeruginosa | Sangeorzan et al., 1990\(^22\) |
| 37         | Female | UL            | NS                        | 10 years                    | 783         | No                 | Yes                                  | No               | P. aeruginosa | Chiappe et al., 2016\(^31\) |
| 28         | Female | Perineum, trunk, face | NS                      | 10 years                    | 100         | Yes                | Yes                                  | No               | P. aeruginosa | El Baze et al., 1991\(^13\) |
| 37         | Male | Buttocks      | NS                        | 100                         | No          | Yes                | Yes                                  | No               | P. aeruginosa | Tornero et al., 1999\(^20\) |
| 44         | Female | Eye, genitalia, perineum, buttocks | NS                | 5 years                     | 67          | No                 | Yes                                  | No               | P. aeruginosa | Present paper |

NS: Not stated, LL: Lower limb, UL: Upper limb, P. aeruginosa: Pseudomonas aeruginosa, MRSA: Methicillin-resistant Staphylococcus aureus, MSSA: Methicillin-sensitive Staphylococcus aureus, NTM: Nontuberculous mycobacterium, HIV: Human immunodeficiency virus.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Barker L. The clinical symptoms, bacteriologic findings and postmortem appearances in cases of infection of human beings with the bacillus pyocyanus. JAMA 1897;29:213-6.
2. Greene SL, Su WP, Muller SA. Ecthyma gangrenosum: Report of clinical, histopathologic, and bacteriologic aspects of eight cases. J Am Acad Dermatol 1984;11:781-7.
3. van den Broek PJ, van der Meer JW, Kunst MW. The pathogenesis of ecthyma gangrenosum. J Infect 1979;1:263-7.
4. Hummer D, Siegman-Igra Y, Morduchowicz G, Pitlik SD. Ecthyma gangrenosum without bacteremia. Report of six cases and review of the literature. Arch Intern Med 1987;147:299-301.
5. Vaiman M, Lazarovitch T, Heller L, Lotan G. Ecthyma gangrenosum and ecthyma-like lesions: Review article. Eur J Clin Microbiol Infect Dis 2015;34:633-9.
6. Bettens S, Daelewe B, Glopuczynski Y, Schoevaerts D, Swine C. Ecthyma gangrenosum in a non-neutropaenic, elderly patient: Case report and review of the literature. Acta Clin Belg 2008;63:394-7.
7. Kim EJ, Foad M, Travers R. Ecthyma gangrenosum in an AIDS patient and normal neutrophil count. J Am Acad Dermatol 1999;41:840-1.
8. Martínez-Longoria CA, Rosales-Solis GM, Ocampo-Garza J, Guerrero-González GA, Ocampo-Candiani J. Ecthyma gangrenosum: A report of eight cases. An Bras Dermatol 2017;92:698-700.
9. Gençer S, Ozer S, Ege Gül A, Doğan M, Ak O. Ecthyma gangrenosum without bacteremia in a previously healthy man: A case report. J Med Case Rep 2008;2:14.
10. Yan W, Li W, Mu C, Wang L. Ecthyma gangrenosum and multiple nodules: Cutaneous manifestations of Pseudomonas aeruginosa sepsis in a previously healthy infant. Pediatr Dermatol 2011;28:204-5.
11. Chuang CH, Wang YH, Chang HJ, Chen HL, Huang YC, Lin TY, et al. Shanghai fever: A distinct pseudomonas aeruginosa enteric disease. Gut 2014;63:276-43.
12. El-Sherif NA, El-Mangush IM, El-Dibany SA. Ecthyma gangrenosum without Pseudomonas bacteremia in an immunocompetent healthy adult – Special issue. Int J Clin Dermatol Res 2017;82:1-3.
13. Cohen N, Capua T, Bilavska E, Dias-Polak H, Levin D, Grisaru-Soen G. Ecthyma gangrenosum skin lesions in previously healthy children. Acta Paediatr 2015;104:134-8.
14. Vaiman M, Lasarowitch T, Heller L, Lotan G. Ecthyma gangrenosum versus ecthyma-like lesions: Should we separate these conditions? Acta Dermatovenerol Alp Pannonica Adriat 2015;24:69-72.
15. Ivanaviciene J, Chirch L, Grant-Kels JM, Kerr PE, Finch J. Ecthyma gangrenosum secondary to meticillin-sensitive Staphylococcus aureus. Int J Womens Dermatol 2016;2:89-92.
16. Burgner D, Eagles G, Burgess M, Procopis P, Rogers M, Muir D, et al. Disseminated invasive infection due to Metarrhizium anisopliae in an immunocompromised child. J Clin Microbiol 1998;36:1146-50.
17. Aygencel G, Dibzyaz M, Sahin G. Burkholderia cepacia as a cause of ecthyma gangrenosum-like lesion. Infection 2008;36:271-3.
18. Son YM, Na SY, Lee HY, Baek JO, Lee JR, Roh JY, et al. Ecthyma gangrenosum: A rare cutaneous manifestation caused by Stenotrophomonas maltophilia in a leukemic patient. Ann Dermatol 2009;21:389-92.
19. Del Pozo J, Garcia-Silva J, Almagro M, Martinez W, Nicolas R, Fonseca E, et al. Ecthyma gangrenosum-like eruption associated with Morganella morganii infection. Br J Dermatol 1998;139:520-1.
20. Obasi OE, Osoba AO, Raddadi AA. Ecthyma gangrenosum in Saudi Arabia. Saudi Med J 2007;28:1741-4.
21. Uludokumaci S, Balkan Il, Mete B, Ozaras R, Saltoglu N, Soysal T. Ecthyma gangrenosum-like lesions in a febrile neutropenic patient with simultaneous Pseudomonas sepsis and disseminated fusariosis. Turk J Haematol 2013;30:321-4.
22. Sangoorzanz AJ, Bradley SF, Kauffman CA. Cutaneous manifestations of pseudomonas infection in the acquired immunodeficiency syndrome. Arch Dermatol 1990;126:832-3.
23. el Baze P, Thyss A, Vinti H, Deville A, Dellamonica P, Ortonne JP. A study of nineteen immunocompromised patients with extensive skin lesions caused by Pseudomonas aeruginosa with and without bacteremia. Acta Derm Venereol 1991;71:411-5.
24. Nelson MR, Barton SE, Langtrey JA, Gazzard BG. Ecthyma gangrenosum without bacteremia in an HIV seropositive male. Int J STD AIDS 1991;2:295-6.
25. Berger TG, Kaveh S, Becker D, Hoffman J. Cutaneous manifestations of Pseudomonas infections in AIDS. J Am Acad Dermatol 1995;32:279-80.
26. Tomoro C, Ricart C, Arnedo AL, Baesa R. Non-bacteremic ecthyma gangrenosum in a patient with human immunodeficiency virus infection. Rev Clin Esp 1999;199:332-3.
27. Khan MO, Montecalvo MA, Davis I, Wormser GP. Ecthyma gangrenosum in patients with acquired immunodeficiency syndrome. Cutis 2006;66:121-3.
28. Cao T, Combs A, Rubenstein E. Ecthyma gangrenosum in a patient with HIV/AIDS. J Am Acad Dermatol 2011;64(5):AB101.
29. Ungraspert P, Permpalung N, Kue-A-Pai P, Ammannagari N, Chongnarungsin D. A rare case of ecthyma gangrenosum associated with methicillin-resistant Staphylococcus aureus infection. J Infect Chemother 2013;19:761-3.
30. Techatawepisarn T, Chiewchanvit S, Salee P, Mahanapub P, Baosoung V, Praparattanapan J. Ecthyma gangrenosum-like lesions associated with disseminated nontuberculous mycobacterial infection in an HIV-infected patient. Southeast Asian J Trop Med Public Health 2013;44:649-54.
31. Chiappe A, Astrocondor L, Chávez G, García Y, Montalvo R. Malignant otitis externa with ecthyma gangrenosum in an HIV-positive patient [Otitis externa maligna con ectima gangrenoso en un paciente con infección por VIH]. Infectio 2016;20:38-41.
32. Buñfière-Morgado A, Demongeot C, Battistella M, Taieb F, Viguier M, Rybojad M, et al. Ecthyma gangrenosum associated with infection involving a methicillin-sensitive, panton-valentine-negative strain of Pseudomonas aeruginosa septicemia: Evidence in favour of a broader definition. Clin Exp Dermatol 2017;42:324-7.
33. Maccheron LJ, Groeneveld ER, Ohlrich SJ, Hilford DJ, Beckingsale PS. Ecthyma gangrenosum without bacteraemia: Evidence in favour of a broader definition. Clin Exp Dermatol 2017;42:324-7.
34. Fonseca E, Gazitúa F, Infante-Cossio P. Ecthyma gangrenosum in the eyelid. J Craniofac Surg 2017;29:531-2.
35. Ungprasert P. Ecthyma gangrenosum in patients with acquired immunodeficiency syndrome. Cutis 2000;66:121-3.
36. Ferguson L, Chong H, Singh M. Ecthyma gangrenosum without bacteremia: Evidence in favour of a broader definition. Clin Exp Dermatol 2017;42:324-7.
37. Maccheron LJ, Groeneveld ER, Ohlrich SJ, Hilford DJ, Beckingsale PS. Ecthyma gangrenosum without bacteraemia: Evidence in favour of a broader definition. Clin Exp Dermatol 2017;42:324-7.
38. Nair IA, Babyo A, Emezie AU, Sani NO. Surveillance for antibiotic resistance in Nigeria: Challenges and possible solutions. Trends Med Res 2015;10:106-13.